- 全部删除
- 您的购物车当前为空
Lys(CO-C3-p-I-Ph)-O-tBu 是一种药代动力学调节基团(PK modifier),它能优化PSMA配体的PK特性。该化合物通过提高与白蛋白的结合能力来延长PSMA配体在血浆中的停留时间,同时降低唾液腺的吸收率,可能有助于延长活性化合物的半衰期。此外,Ac-PSMA-trillium 作为一种PSMA靶向化合物,适用于经过不同放射性同位素修饰,实现多种生物学应用。例如,标记111In后,Ac-PSMA-trillium 可用作DOTA螯合剂和显像剂;而标记225Ac后,则可用作Macropa螯合剂,用于针对转移性去势抵抗性前列腺癌(mCRPC)的靶向放射性核素疗法(TRT)。
Lys(CO-C3-p-I-Ph)-O-tBu 是一种药代动力学调节基团(PK modifier),它能优化PSMA配体的PK特性。该化合物通过提高与白蛋白的结合能力来延长PSMA配体在血浆中的停留时间,同时降低唾液腺的吸收率,可能有助于延长活性化合物的半衰期。此外,Ac-PSMA-trillium 作为一种PSMA靶向化合物,适用于经过不同放射性同位素修饰,实现多种生物学应用。例如,标记111In后,Ac-PSMA-trillium 可用作DOTA螯合剂和显像剂;而标记225Ac后,则可用作Macropa螯合剂,用于针对转移性去势抵抗性前列腺癌(mCRPC)的靶向放射性核素疗法(TRT)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | Lys(CO-C3-p-I-Ph)-O-tBu, a pharmacokinetic modifier (PK modifier), enhances the pharmacokinetic properties of PSMA ligand molecules by increasing their residence time in plasma through improved binding to albumin and reducing absorption by the salivary glands, potentially extending the active compound's half-life. Moreover, Ac-PSMA-trillium is an effective PSMA-targeting compound for various biological applications when modified with different radioactive isotopes. When labeled with 111 In, it serves as a DOTA chelating agent and imaging agent. Alternatively, when labeled with 225 Ac, it acts as a Macropa chelator for targeted radionuclide therapy (TRT) in researching metastatic castration-resistant prostate cancer (mCRPC) [1] [2]. |
分子量 | 474.38 |
分子式 | C20H31IN2O3 |
CAS No. | 2703051-80-1 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.